









市場行情
/
股票
/
nasdaq-svra
/

Savara Inc

SVRA

6.450USD

+0.050+0.78%

收盤 12/26, 16:00（美東）報價延遲15分鐘

1.11B總市值

虧損本益比TTM



Savara Inc

6.450

+0.050+0.78%

概覽公司財務分析

概覽

公司

財務

分析

關於 Savara Inc 公司

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Savara Inc簡介



公司代碼SVRA

公司名稱Savara Inc

上市日期Jun 25, 2001

CEOPauls (Matthew)

員工數量59

證券類型Ordinary Share

年結日Jun 25

公司地址6836 Bee Cave Road

城市AUSTIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編78746

電話151285113796

網址https://savarapharma.com/

公司代碼SVRA

上市日期Jun 25, 2001

CEOPauls (Matthew)

Savara Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

Mr. Richard J. (Rick) Hawkins

Independent Director

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

Dr. Raymond Dennis (Ray) Pratt, M.D.

Chief Medical Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

其他

60.35%

持股股東

佔比

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

其他

60.35%

股東類型

持股股東

佔比

Investment Advisor

28.82%

Venture Capital

19.47%

Hedge Fund

18.75%

Investment Advisor/Hedge Fund

9.69%

Private Equity

5.63%

Individual Investor

2.15%

Research Firm

1.54%

Bank and Trust

0.11%

Insurance Company

0.02%

其他

13.80%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

2023Q2

170

92.45M

81.05%

-2.68M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

New Enterprise Associates (NEA)

24.47M

14.16%

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

10.18%

Jun 30, 2025

Deerfield Management Company, L.P.

7.96M

4.61%

Jun 30, 2025

VR Adviser, LLC

8.88M

5.14%

+5.63M

+172.72%

Jun 30, 2025

TCG Crossover Management, LLC

12.36M

7.15%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

6.63%

Jun 30, 2025

Nantahala Capital Management, LLC

8.33M

4.82%

+250.00K

+3.10%

Jun 30, 2025

The Vanguard Group, Inc.

8.43M

4.88%

+334.73K

+4.13%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.54M

4.94%

-164.33K

-1.89%

Jun 30, 2025

Emerald Advisers LLC

5.72M

3.31%

+616.10K

+12.07%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

1.24%

Texas Capital Texas Small Cap Equity Index ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.13%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.07%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

ProShares Hedge Replication ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.24%

Texas Capital Texas Small Cap Equity Index ETF

佔比0.24%

ProShares Ultra Nasdaq Biotechnology

佔比0.13%

iShares Micro-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.07%

Texas Capital Texas Equity Index ETF

佔比0.05%

iShares Biotechnology ETF

佔比0.03%

ProShares Hedge Replication ETF

佔比0.03%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.03%

iShares Russell 2000 Growth ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Savara Inc的前五大股東是誰？



Savara Inc的前五大股東如下：
New Enterprise Associates (NEA)
持有股份：24.47M
佔總股份比例：14.16%。
Bain Capital Life Sciences Investors, LLC
持有股份：17.60M
佔總股份比例：10.18%。
Deerfield Management Company, L.P.
持有股份：7.96M
佔總股份比例：4.61%。
VR Adviser, LLC
持有股份：8.88M
佔總股份比例：5.14%。
TCG Crossover Management, LLC
持有股份：12.36M
佔總股份比例：7.15%。